Skip to content
0032-spray

AdaptDx Disinfecting Recommendations

The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.

ClaudioLagunas Claudio Lagunas, OD View all testimonials

For Practices

Subclinical AMD Detection

Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.

For Patients

Protect Your Eyesight

Talking to your eye doctor about risk factors or trouble seeing at night may help detect macular degeneration early enough to hopefully delay progression of disease.

Breakthrough Technology Meets High-Touch Patient Care

Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.

The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.

RyanPowell Ryan Powell, OD View all testimonials

Latest News & Upcoming Events

View More
Article: July 16, 2021 | Women in Optometry

On Our Way To Better Days

How can we make timely referrals the norm, not the exception? Jessica Haynes, OD, shares how technology takes the guesswork out of monitoring and managing AMD suspects.

Our Blog: July 15, 2021

If Hindsight is 20/20, Foresight is Making a Difference

Dr. Lou shares how he needed to rethink AMD, and is proud to report that this allowed him to make a marked difference in disease management.

Article: June 30, 2021 | Review of Optometric Business

AMD & COVID: What Has the Pandemic’s Impact Been on Those with AMD?

Read how AMD went undetected due to delayed care because a patient feared catching COVID at the doctor’s office.